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Summary
Objective: Determining the identity of hepatitis C virus (HCV) genotypes in liver disease has key
implications for ascertaining the duration of antiviral therapy and disease prognosis. We
investigated the presence of various genotypes of HCV among 69 chronic liver diseased (CLD)
patients with chronic HCV infection.
Methods: Sixty-nine consecutive subjects with underlying chronic hepatitis (n = 28), cirrhosis
(n = 35), and hepatocellular carcinoma (n = 6), diagnosed by clinical, biochemical, and histolo-
gical means, were studied. Hepatitis B virus (HBV) and HCV diagnostic markers were used. HCV-
RNAwas extracted from sera of HCV-infected subjects and subsequently the HCV genotypes were
determined using a commercial line probe assay (Inno-LiPA HCV II).
Results: Of the 69 CLD cases screened for possible markers of HBV and HCV infection, 39 (57%)
were positive for HBV and 30 (43%) were HCV infected. The overall HCV-RNA positivity was 77%
(23/30). Of these, the majority were genotype 1b (13/23, 57%), followed by 1a (6/23, 26%),
mixed genotypes 3 and 4 (3/23, 13%), and mixed pattern of 1a, 1b, and 4 (1/23, 4.3%). The
genotype 1b infected subjects demonstrated significantly elevated transaminase (ALT) levels
(p < 0.05) as compared with the other non-1b HCV genotypes.* Corresponding author. Tel.: +91 44 22542929; fax: +91 44 22542939.
E-mail address: saravanan@yrgcare.org (S.P. Thyagarajan).
1201-9712/$32.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2008.02.006
Conclusions: The predominance of HCV genotype 1b among CLD patients could pose a major
challenge for the efficient management of HCV disease and the development of effective ther-
apeutic interventions in peninsular India.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis C virus (HCV) infection is estimated toafflict approxi-
mately 180 million people worldwide, i.e., about 3% of the
world’s population. Six major HCV genotypes have been
described and these genotypes can differ up to 30% from each
other in nucleotide sequence.1 Globally, 3—4 million persons
are newly infected each year, with genotype 1 being the most
commonintermsofprevalence, followedbygenotypes2and3.
The other genotypes, namely 4, 5, and 6, are reported to have
specific geographical distributions. While the acute phase of
HCV infection is reported tobeasymptomatic in themajorityof
cases, this could however progress to chronic stage in approxi-
mately 70—80% of affected individuals.2,3 This consequently
could lead to progressive liver damage and cirrhosis, with
increased risk of hepatocellular carcinoma (HCC).4
HCV infection is reported to be responsible for 15—20% of
all chronic liver disease (CLD) cases and approximately 5—
10% of all HCC cases in India.5 Liver disease in HCV does not
occur in a linear and predictable fashion, but is instead
influenced by factors such as genotype, viral load, duration
and age of infection, body weight, alcohol consumption, and
concurrent infection by hepatitis B virus (HBV) or human
immunodeficiency virus (HIV). While each of the viral and
host factors influence the disease, HCV genotype has
emerged as an independent factor, which largely influences
the duration and treatment outcome.6
Genetic variability is increasingly recognized as an impor-
tant factor to be considered in the prognosis, monitoring, and
outcome of HCV mediated CLD.7 A recent Indian study
reported steatosis in 70% of liver biopsy samples from chronic
HCV cases.8 Furthermore, another study documented the
close association of HCV genotype 3 with steatosis and
fibrosis.9 Genotype 1b is less responsive to interferon-a
(IFN-a) therapy compared to genotypes 2 and 3, which
necessitates measures to track down the different HCV
genotypes.10,11 The assessment of HCV genotypes has
become a pivotal determinant in deciding the treatment
duration and dosage. Although there are several reports
describing the prevalence of HCV genotypes in India, most
of them have reported on the preponderance of genotype 3 in
the north,9,12—19 whereas a few others from the south have
reported genotype 1 to be the most common.20,21 However,
none have correlated the association of HCV genotypes with
liver disease severity in the Indian sub-continent. Therefore,
we studied the prevalence of various genotypes of HCVamong
subjects with CLD and chronic HCV infection.
Patients and methods
Study design
Sixty-nine consecutive histopathologically proven CLD cases
referred from various gastroenterology departments of Gov-ernment hospitals to the National Reference Center for Viral
Hepatitis, Department of Microbiology, Dr ALM PG IBMS,
University of Madras, Chennai, India, were studied. The study
was approved by the Institutional Review Board (IRB) of the
University of Madras.
Patients
The available biochemical, clinical, and liver histopatholo-
gical data were used to correlate with the virological profile.
The severity of liver disease was determined by histological
methods and graded based on histological activity index from
0 to 18 and the degree of hepatic fibrosis from 0 to 4 staging
(modified Knodell’s).22 All subjects were interviewed on the
basis of a pre-designed questionnaire regarding occupation,
past history of jaundice (nature, etiology, and outcome),
blood transfusion, surgery/dental/gynecological proce-
dures, radiological intervention, exposure to syringes and
needles, ear pricks, sharing of razors/blades, mother being
HBsAg and/or anti-HCV positive, information on high-risk
behaviors such as intravenous drug (IVD) abuse, sexual pro-
miscuity, tattooing, etc. None of the patients had a history of
hemodialysis or organ transplantation.
Specimens and methods
Five milliliters of blood were collected, and serum was
separated, aliquoted, and stored at 70 8C until further
testing. The following markers of HBV and HCV using com-
mercial ELISA kits viz. HBsAg, anti-HBs, HBeAg/anti-HBe
(Biorad Laboratories, USA), and anti-HCV (Murex Diagnostics,
UK) with known positive and negative controls were used.
Qualitative HBV-DNA polymerase chain reactions (PCR)23 and
qualitative HCV-RNA reverse transcriptase-polymerase chain
reactions (RT-PCR)24 were performed with appropriate posi-
tive and negative controls. The sensitivities of PCR assays
reached 10 copies of HBV-DNA and 50 copies of HCV-RNA per
specimen, as determined by testing 10-fold serial dilutions of
HBV-DNA/HCV-RNA at known concentrations. HCV genotyping
was carried out using a commercial type-specific detection
system targeting the PCR-amplified 50 non-coding region (50
NCR) (Inno-LiPA, Innogenetics, Belgium) according to the
manufacturer’s instructions.
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences software (SPSS for Windows, version
13.0, Chicago, IL, USA). The median values of alanine trans-
aminase (ALT) levels according to age, HBV/HCV, with or
without DNA/RNA, and liver status, were analyzed by non-
parametric Mann—Whitney U-tests. In addition, whenever
variables were continuous, the results were analyzed using
the t-test. All p values were two-sided.
Table 1 Demographic and clinical characteristics of liver disease patients according to hepatitis infection status (N = 69)
Finding HBV alone (n = 39) HCV alone (n = 30) p-Value
Age 55 (7) 56 (9) 0.822
Sex 0.310
Male 28 (72%) 24 (80%)
Female 11 (28%) 6 (20%)
HBV-DNA/HCV-RNA by PCR 20 (51%) 23 (77%) 0.000
Hepatic enzyme (ALT) 70 (56—120) 75 (50—120) 0.741
<50 IU/l 8 (21%) 8 (27%)
51—100 IU/l 19 (49%) 12 (40%)
>100 IU/l 12 (31%) 10 (33%)
Liver disease 0.468
Chronic hepatitis with cirrhosis (n = 63) 37 (95%) 26 (87%)
HCC (n = 6) 2 (5%) 4 (13%)
HBV, hepatitis B virus; HCV, hepatitis C virus; PCR, polymerase chain reaction; ALT, alanine transaminase; HCC, hepatocellular carcinoma.
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The clinical and demographic characteristics of 69 CLD
patients, consisting of 91% (63/69) with chronic hepatitis
(with cirrhosis) and 9% (6/69) with HCC are shown in Table 1.
The age range of the patients was 40 to 65 years. Figure 1
shows the risk factors associated with HBV and HCV etiology
among the 69 CLD cases studied. Of the 69 CLD cases
screened for serological and molecular markers of HBV and
HCV, 39 (57%) were HBsAg positive and 30 (43%) were positive
for HCV infection. Among the HBV infected CLD cases, 26%Figure 1 (a) Risk factors involved in hepatitis B virus (HBV)
infected liver disease patients (n = 39). (b) Risk factors involved
in hepatitis C virus (HCV) infected liver disease patients (n = 30).(10/39) were HBeAg positive and 74% (29/39) were anti-HBe
positive, and none of them were anti-HBs positive. Twenty
(51%) cases were positive for HBV-DNA and 23 (77%) were
positive for HCV-RNA among the HBV and HCV infected cases
respectively. None of these cases had dual infection of both
HBVand HCV. All our study cases were tested and found to be
negative for HIV-1/HIV-2 infection.
Among the 63 chronic hepatitis patients with cirrhosis,
59% (37/63) were HBV infected and 41% (26/63) were HCV
infected. Furthermore, among the six cases with HCC, 67%
(4/6) were HCV infected and 33% (2/6) were HBV infected.
Among the CLD cases studied based on HBV and HCV etiol-
ogies, a significantly ( p < 0.05) higher level of liver disorders
were observed among viremic cases by qualitative PCR as
compared to non-viremic HBV and/or HCV infected cases
(Table 2). All six HCC patients were positive by diagnostic
PCR (two HBV-DNA and four HCV RT-PCR) (Figure 2).
Four types of HCV genotypes (1a, 1b, 3 and 4, and 1a, 1b,
with 4) were detectable among HCV RT-PCR positive samples
studied by the Inno-LiPA method (Figure 3). When all 23 HCV-
RNA positive cases were subjected to HCV genotyping, the
majority of these were found to be infected with genotype 1b
(n = 13, 57%), followed by 1a (n = 6, 26%), mixed genotypes of
3 and 4 (n = 3, 13%), and one mixed pattern of 1a, 1b, 4 (4%)
(Figure 3). The level of transaminase (ALT) was significantlyFigure 2 Hepatitis B virus (HBV) and hepatitis C virus (HCV) in
liver disease patients (N = 69).
Table 2 Characteristics according to viremic and non-viremic hepatitis infection status (HBV-DNA and HCV-RNA by qualitative
PCR)
Findings Viremic (n = 43) Non-viremic (n = 26) p-Value
Age 57 (8) 53 (6)
Sex
Male 31 (72%) 21 (81%) 0.304
Female 12 (28%) 5 (19%)
Virology
HBV 20 (47%) 19 (73%)
HCV 23 (53%) 7 (27%)
LFT (ALT) 90 (60—140) 60 (50—72) 0.056
<50 IU/l 8 (19%) 8 (31%)
51—100 IU/l 16 (37%) 15 (58%)
>100 IU/l 19 (44%) 3 (12%)
Liver status 0.019
Chronic hepatitis with cirrhosis 37 (86%) 26 (100%)
HCC 6 (14%) 0 (0%)
HBV, hepatitis B virus; HCV, hepatitis C virus; PCR, polymerase chain reaction; LFT, liver function test; ALT, alanine transaminase; HCC,
hepatocellular carcinoma.
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compared to non-1b HCV genotypes.Discussion
HCV genetic variability is increasingly recognized as a key
factor in the prognosis and outcome of CLD. Current guide-
lines recommend its inclusion in HCV treatment algorithms as
a means of optimizing efficacy and maximizing the chances
for successful treatment outcome.25 Different HCV isolates
from across the world show substantial nucleotide sequence
variability throughout the viral genome. The distributions of
HCV genotypes vary according to the geographic region and
seem to be related to their time of divergence. It is important
to note that this distribution is not static; as the frequency of
infection increases, as populations migrate, and as modes of
transmission change from transfusion to IVD use, the pre-Figure 3 Prevalence of hepatitis C virus (HCV) genotypevalence of the different genotypes and subtypes within a
country or region changes.
Several studies have shown that epidemiological para-
meters such as age, risk factors, and infection duration
may be associated with genotype.3,4,6,10,11 In Latin America,
Europe, the USA, and Japan, HCV genotypes 1, 2, and 3
account for the majority of infections, with subtype 1b being
the most prevalent.1 Fascinatingly, while most of the north
Indian data12—19 suggest a high prevalence of genotype 3,
studies from the south20,21 show a high proportion of geno-
type 1. In one report, HCV genotypes were studied in a high-
risk population,20 while in the other, a tribal population was
studied.21 From the available data, it is almost consensus
that genotype 1 is the more common in this part of India, but
it is more likely that the variability in other parts of India is
due to the choice of special populations with small numbers
of study subjects. The difference between our results and
those from other Indian investigators suggests the lowers among HCV infected liver disease patients (n = 23).
HCV genotype 1b in South India 517prevalence (n = 3) of subtype 3. We have clearly demon-
strated that genotype 1 (83%) remains the most common
genotype with a preponderance of genotype 1b (57%) to 1a in
southern India. Furthermore, the prevalence of HCV geno-
type 1 concords with other earlier reports from this part of
South India.20 Conversely, we suggest that the low prevalence
of genotype 3 and very high proportion of genotype 1b among
CLD cases may pose a major challenge for the efficient
management and development of effective therapeutic stra-
tegies in this part of the country.12—19 Studies have suggested
that some HCV genotypes, especially genotype 1b, lead to a
more severe course and appear to be associated with distinct
liver manifestations.26,27
While evaluating the association of the different geno-
types with demographic data, we could not find any notable
difference in genotype distribution among genders. However,
investigations in relation to age indicated that older age was
strongly associated with genotype distribution.28 Genotype 1
was common among older patients, while others (viz. geno-
types 3 and 4, and 1a, 1b and 4) were common among younger
subjects. Therefore, conceptually we can assume that infec-
tion with genotype 1b in South India occurred much further in
the past than with other genotypes, subtypes, and mixed
inter-genotype viruses. Early investigations from the USA
failed to find an association between HCV genotypes and
transmission modes.29 However, investigators from Europe
reported that patients with a history of blood transfusion
were most often infected with genotype 1b and IVD abusers
with genotype 3a.30—35 Our results have shown that genotype
1b is more predictive of blood transfusion and tattooing, in
agreement with the above reports. Although we did not
confirm the correlation of genotype 3 and 4 with any parti-
cular mode of HCV transmission, the presence of this geno-
type as the independent negative risk factor for blood
transfusion may suggest certain other routes of transmission.
Additionally, it is possible to conceptualize that the relatively
high prevalence of mixed inter-genotypes 3 and 4 (13%)
among our cases reflects a possible re-infection in the same
subjects, although we were unable to associate these geno-
types with the transmission mode. Moreover, the association
of genotype 1 (mostly subtype 1b) with advanced HCV-
related liver disease has been proven repeatedly in this part
of India. Therefore, we assume that this association could be
paradigmatic of earlier infections with a similar subtype in
comparison with subtype 3 and mixed infection with subtype
4. Earlier reports also suggested that subtype 1b could be
associated with a more advanced stage of liver dis-
ease.34,36,37 Steatosis is reported to be an important co-
factor of liver necro-inflammation and is believed to be
central for progression to fibrosis among chronic HCV
cases.38—40 This has recently been confirmed among subtype
3 infected north Indian subjects.9 However, we failed to
notice this correlate among our study subjects.
Despite the increasing understanding of the biologic and
clinical aspects of HCV infection, this virus continues to be a
major challenge to both virologists and physicians in the area
of treatment and clinical management. Thus, we conclude
that HCV is the second most prevalent virus among the CLD
cases in southern India. It is clinically intriguing that while
HCV genotype 3 is more prevalent in northern India with
significant hepatic steatosis and fibrosis,9 the intrinsically
INF-a resistant HCV genotype 1b remains highly prevalent insouthern India. The role of subtype 1b that reportedly cor-
relates with higher histological activity reflects the poten-
tially pathogenic feature of this subtype, with consequences
such as longer persistence and more aggressive influence on
disease outcome that requires careful analysis in prospective
settings. Hence, there is an urgent need for controlled multi-
centric clinical trials in India to clarify the potential risk
factors, including specific HCV genotypes and treatment
outcome. Alternative management and treatment strategies
are also to be designed for managing HCV mediated CLD in
India.
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